1 |
ClinicalTrials.gov (NCT00002338) The Safety and Effectiveness of 935U83 in HIV-Infected Patients. U.S. National Institutes of Health.
|
2 |
Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 1996 Dec;40(12):2842-7.
|
3 |
5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.
|
4 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
5 |
Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
|
6 |
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
|
7 |
A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
|
8 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
9 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
|
10 |
Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
|
11 |
2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
|
|
|
|
|
|
|